Interleukin-17 Facilitates the Immune Suppressor Capacity of High-Grade Glioma-Derived CD4 (+) CD25 (+) Foxp3 (+) T Cells Via Releasing Transforming Growth Factor Beta

Scandinavian Journal of Immunology

Volumn 80, Issue 2, 2014, Pages 144-150

  Liang, H ^a   Yi, L ^a   Wang, X ^a   Zhou, C ^a   Xu, L ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHILD; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLIOBLASTOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; INTERLEUKIN-17; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-17; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; YOUNG ADULT;

EID: 84903892195     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12185     Document Type: Article

References (23)

1. Cunliffe CH, Fischer I, Parag Y, Fowkes ME. State-of-the-art pathology: new WHO classification, implications, and new developments. Neuroimaging Clin N Am 2010;20:259-71.
2. Mineo JF, Bordron A, Baroncini M et al. Prognosis factors of survival time in patients with glioblastoma multiforme: a multivariate analysis of 340 patients. Acta Neurochir 2007;149:245-53.
3. Ohkura N, Hamaguchi M, Sakaguchi S. FOXP3 + regulatory T cells: control of FOXP3 expression by pharmacological agents. Trends Pharmacol Sci 2011;32:158-66.
4. Jacobs JFM, Idema AJ, Bol KF et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 2010;225:195-9.
5. Jadidi-Niaragh F, Mirshafiey A. Th17 cell, the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol 2011;74:1-13.
6. Leppkes M, Becker C, Ivanov II et al. ROR gammat-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009;136:257-67.
7. Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 2010;39:369-83.
8. Brackmann S, Andersen SN, Aamodt G et al. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand J Gastroenterol 2009;44:46-55.
9. Voo KS, Wang YH, Santori FR et al. Identification of IL-17-producing FOXP3 + regulatory T cells in humans. Proc Natl Acad Sci U S A 2009;106:4793-8.
10. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 2010;159:120-30.
11. Xu L, Xiao H, Xu M et al. Cell immunoglobulin- and mucin domain-containing molecule-4 (TIM4) contributes to tumor tolerance. J Biol Chem 2011;286:36694-9.
12. Elkord E, Alcantar-Orozco EM, Dovedi SJ, Tran DQ, Hawkins RE, Gilham DE. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010;10:1573-86.
13. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011;140:957-65.
14. Yang S, Wang B, Guan C et al. Foxp3 + IL-17 + T cells promote development of cancer-initiating cells in colorectal cancer. J Leukoc Biol 2011;89:85-91.
15. Semenza GL. Oxygen sensing, homeostasis, and disease. N Engl J Med 2011;365:537-47.
16. Jensen R, Ragel B, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 2006;78:233-47.
17. Aguilar LK, Guzik BW, Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J Cell Biochem 2011;112:1969-77.
18. Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD. Prognostic significance of CD8 + T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 2011;58:1107-16.
19. Chiang CL-L, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011;30:150-82.
20. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3 + regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 2011;60:909-18.
21. Donkor M, Sarkar A, Savage P et al. T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-beta1 cytokine. Immunity 2011;35:123-34.
22. Zhang JP, Yan J, Xu J et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-9.
23. Wang K, Grivennikov SI, Karin M. Implications of anti-cytokine therapy in colorectal cancer and autoimmune diseases. Ann Rheum Dis 2013;72:ii100-3.